November 5, 2025
1 min read

AstraZeneca adds $136M investment to Chinese inhalants plant

AstraZeneca is pouring $136 million more into the expansion of an inhalants production base in China, bringing its total investment at the site to $886 million.

Leave a Reply

Your email address will not be published.

Previous Story

Making protein accessible: Quick commerce steps up to meet India’s nutrition gap – The Times of India

Next Story

Remote Health Monitoring Increases Doctors’ Ability To See More Patients

Previous Story

Making protein accessible: Quick commerce steps up to meet India’s nutrition gap – The Times of India

Next Story

Remote Health Monitoring Increases Doctors’ Ability To See More Patients

Latest from Blog

ROFI Drives New Approach to Crop Nutrition

With input costs continuing to pressure farm budgets, some growers are making difficult decisions to reduce fertilizer application rates. While that strategy may ease upfront expenses, it is also accelerating a broader
Go toTop